fludarabine has been researched along with mitoxantrone in 139 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (10.07) | 18.2507 |
| 2000's | 83 (59.71) | 29.6817 |
| 2010's | 41 (29.50) | 24.3611 |
| 2020's | 1 (0.72) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV | 1 |
| Bosanquet, AG; Chapman, CS; Hutchinson, RM; Parker, AN | 1 |
| Bendandi, M; Tura, S; Zinzani, PL | 1 |
| Calvert, L; Claxton, D; Durett, A; Giralt, S; Hamer, J; Kantarjian, H; Khouri, I; Liang, J; Talpaz, M; Tibbits, P | 1 |
| Calvert, L; Deisseroth, AB; Feldman, E; Hester, J; Kantarjian, HM; Korbling, M; Liang, J; Rios, MB; Smith, TL; Talpaz, M | 1 |
| Gandhi, V; Loughlin, S; Plunkett, W; Zwelling, LA | 1 |
| Estey, EH; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
| Chandra, J; Keating, M; McConkey, DJ; McDonnell, TJ; Plunkett, W; Reed, JC; Wright, S | 1 |
| Bendandi, M; Gherlinzoni, F; Magagnoli, M; Merla, E; Tura, S; Zinzani, PL | 1 |
| O'Brien, S | 1 |
| Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G | 1 |
| Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P | 1 |
| Emmanouilides, C; Kunkel, L; Rasti, S; Rosen, P; Territo, M | 1 |
| Bellosillo, B; Colomer, D; Gil, J; Montserrat, E; Pons, G; Villamor, N | 1 |
| Estey, E; Feldman, EJ; Kantarjian, HM; Keating, M; Koller, CA; O'Brien, S; Rios, MB | 1 |
| Bendandi, M; Cellini, C; Gherlinzoni, F; Magagnoli, M; Orcioni, GF; Pileri, SA; Stefoni, V; Tura, S; Zinzani, PL | 1 |
| Molinari, A; Poletti, G; Poletti, V; Salvucci, M; Zaccaria, A; Zanchini, R; Zuffa, E | 1 |
| Au, WY; Choy, C; Kwong, YL; Ng, WM | 1 |
| Crawley, CR; Foran, JM; Gupta, RK; Johnson, PW; Johnson, SA; Lister, TA; Matthews, J; Micallef, IN; Radford, JA; Rohatiner, AZ; Summers, K; Sweetenham, JW | 1 |
| Cabanillas, F; Dang, NH; Hagemeister, FB; Lee, MS; McAda, N; McLaughlin, P; Pate, O; Preti, AH; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A | 1 |
| Chisesi, T; Congiu, AM; Gallamini, A; Gobbi, M; Marino, G; Mattei, D; Nati, S; Pierluigi, D; Rossi, E; Rubagotti, A; Santini, G; Sertoli, MR; Spriano, M; Truini, M; Vimercati, R | 1 |
| Ghalie, R; Gregory, SA; Kraemer, K; Menduni, T; Modiano, M; Rifkin, R; Rubin, A; Vose, J | 1 |
| Braess, J; Büchner, T; Hiddemann, W; Kern, W; Ohnesorge, J; Schleyer, E; Unterhalt, M; Wittmer, E; Wörmann, B | 1 |
| Bonifazi, F; Bonini, A; Castellani, S; Gugliotta, L; Isidori, A; Lemoli, RM; Malagola, M; Martinelli, G; Motta, MR; Piccaluga, PP; Rizzi, S; Tura, S; Visani, G | 1 |
| Ehninger, G; Fiedler, F; Friedrichsen, K; Hänel, A; Hänel, M; Herbst, R; Morgner, A; Neser, S; Nicklisch, M; Teich, M | 1 |
| Eigler, A; Emmerich, B; Endres, S; Loher, F; Meinhardt, G; Siegmund, B; Welsch, J | 1 |
| Battmer, K; Dammann, E; Eder, M; Ganser, A; Hambach, L; Heil, G; Hertenstein, B; Stucki, A | 1 |
| Fox, RM; Grigg, AP; Seymour, JF; Szer, J | 1 |
| Appelbaum, FR | 1 |
| Cabanillas, F; Ford, RJ; Jiang, Y; McLaughlin, P; Medeiros, LJ; Rassidakis, GZ; Sarris, AH; Thomaides, A; Tsimberidou, AM | 1 |
| Anagnostopoulos, A; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Kiamouris, C; Mantzios, G; Nicolaides, C; Papageorgiou, E | 1 |
| Jain, VK; Ogden, JL; Wilder, DD | 1 |
| Bard, V; Foon, KA; LaRocca, RV; Rohatgi, N; Sethuraman, G | 1 |
| Batár, P; Kiss, A; Rák, K; Rejtó, L; Reményi, G; Telek, B; Udvardy, M | 1 |
| Bergmann, M; Busch, R; Emmerich, B; Franke, A; Hallek, M; Hiddemann, W; Hopfinger, G; Pasold, R; Schlag, R; Schmitt, B; Wendtner, CM | 1 |
| Bellosillo, B; Bosch, F; Campo, E; Colomer, D; López-Guillermo, A; Marcé, S; Montserrat, E; Villamor, N | 1 |
| de Fabritiis, P; De Propris, MS; Foa, R; Gentile, M; Giammartini, E; Giannarelli, D; Mandelli, F; Mauro, FR; Meloni, G; Rapanotti, MC | 1 |
| Amir, G; Cohen, Y; Da'as, N; Gillis, S; Polliack, A; Rund, D | 1 |
| Ayala, A; Cabanillas, F; Hagemeister, FB; Hess, M; Lee, MS; McLaughlin, P; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, A; Smith, TL; Tsimberidou, AM; Yang, Y; Younes, A | 1 |
| Böck, HP; Forstpointner, R; Hänel, A; Hartmann, F; Hermann, S; Hiddemann, W; Metzner, B; Pott, C; Repp, R; Rothmann, F; Unterhalt, M; Wandt, H | 1 |
| Antoun, S; Carpiuc, I; Delabarthe, A; Driss, B; Fenaux, R; Griscelli, F; Ribrag, V; Vantelon, JM | 1 |
| Altés, A; Bellosillo, B; Besalduch, J; Bosch, F; Cobo, F; Colomer, D; Esteve, J; Ferrer, A; Giné, E; López-Guillermo, A; Montserrat, E; Perales, M; Ribera, JM; Villamor, N | 1 |
| Alinari, L; Baccarani, M; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Dreyling, M; Hiddemann, W; Unterhalt, M | 1 |
| Abebe, L; Adiga, GU; Wiernik, PH | 1 |
| Balcerzak, SP; Chapman, RA; Dakhil, SR; Fisher, RI; Grogan, TM; Lanier, KS; Lew, D; Miller, TP; Spiridonidis, CH; Velasquez, WS | 1 |
| Bairey, O; Berrebi, A; Lugassy, G; Polliack, A; Rahimi-Levene, N; Shpilberg, O; Shtalrid, M; Shvidel, L | 1 |
| Bongarzoni, V; Buffolino, S; Cimino, G; Montanaro, M; Niscola, P; Scaramucci, L | 1 |
| Bordonaro, R; Cordio, S; Giannitto-Giorgio, C; Giuffrida, D; Manusia, M; Marletta, F; Novello, G; Petralia, G; Restuccia, N; Salice, P; Serraino, D; Todaro, AM; Ursino, M | 1 |
| Debotton, S; Deconinck, E; Dreyfus, F; Ducastelle, S; Fenaux, P; Fruchart, C; Gratecos, N; Ifrah, N; Prébet, T; Stamatoullas, A; Wattel, E | 1 |
| Andreeff, M; Beran, M; Ferrajoli, A; Giles, FJ; Kantarjian, HM; Keating, MJ; Lerner, S; O'Brien, S; Tsimberidou, AM; Wierda, WG | 1 |
| Böck, HP; Dreyling, M; Forstpointner, R; Hänel, A; Hartmann, F; Hermann, S; Hiddemann, W; Metzner, B; Pott, C; Repp, R; Rohrberg, R; Rothmann, F; Unterhalt, M; Wandt, H | 1 |
| Bowen, A; Catovsky, D; Hendry, L; Matutes, E; Swansbury, J | 1 |
| Au, WY; Ho, SL; Kwong, YL; Leung, SY; Mak, W | 1 |
| Aversa, S; Candela, M; Chisesi, T; Congiu, AM; Marino, G; Nati, S; Patti, C; Polacco, A; Porcellini, A; Ravetti, JL; Rizzoli, V; Rubagotti, A; Santini, G; Spriano, M; Vimercati, R; Zoli, V; Zupo, S | 1 |
| Bellosillo, B; Bosch, F; Campo, E; Colomer, D; Espinet, B; Ferrer, A; López-Guillermo, A; Marcé, S; Montserrat, E; Solé, F; Villamor, N | 1 |
| Berthou, C; Casassus, P; Colombat, P; Deconinck, E; Delwail, V; Desablens, B; Foussard, C; Ghandour, C; Gressin, R; Lamy, T; Mahé, B; Maisonneuve, H; Pignon, B; Rachieru, P; Rousselet, MC | 1 |
| Cabanillas, F; Coleman, M; Gregory, SA; Hagemeister, F; Zinzani, PL | 1 |
| Gershanovich, ML; Tikhonova, VV | 1 |
| Ayala, A; Estey, E; Glassman, A; Hagemeister, FB; Hayes, K; Maddox, AM; McLaughlin, P; Preti, HA; Romaguera, J; Samaniego, F | 1 |
| Byrd, JC; Grever, MR; Lin, TS | 1 |
| Naito, K; Ohnishi, K | 1 |
| Adams, DJ; Colvin, OM; Flowers, JL; Rizzieri, DA; Shanks, RH | 1 |
| Ayala, A; Cabanillas, F; Feng, L; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, J; Smith, TL; Tsimberidou, AM; Younes, A | 1 |
| Bao, L; Huang, XJ; Jiang, B; Lu, DP; Lu, J; Lu, XJ; Qiu, JY; Shi, HX; Wang, DB; Wang, FR | 1 |
| Au, WY; Chim, CS; Kwong, YL; Lam, CC; Pang, AW | 1 |
| Januszewicz, EH; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM | 1 |
| Hong, WD; Li, J; Luo, SK; Tong, XZ; Zhao, Y | 1 |
| Bukin, M; Jabłońska, E; Kiersnowska-Rogowska, B; Parfieńczyk, A; Puzewska, W; Rogowski, F | 1 |
| Sikorski, AF; Stebelska, K; Wyrozumska, P | 1 |
| Benson, GM; Clarke, J; Kettle, PJ; Murtagh, E; Wilson, L | 1 |
| Au, WY; Chan, LC; Kwong, YL; Liang, R | 1 |
| Hanamura, A; Hayakawa, M; Naito, K | 1 |
| Januszewicz, EH; Milner, A; Polizzotto, MN; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM | 1 |
| Bulanov, AIu; Chernova, NG; Gretsov, EM; Kalinin, NN; Kravchenko, SK; Kremenetskaia, AM; Mar'in, DS; Petrova, VI; Semenova, EA; Valiev, TT; Vinogradova, IuE; Volkova, IaK; Vorob'ev, AI | 1 |
| Böck, HP; Dreyling, M; Einsele, H; Forstpointner, R; Hänel, A; Hartmann, F; Hiddemann, W; Lehmann, T; Metzner, B; Pott, C; Repp, R; Seymour, JF; Unterhalt, M; Wandt, H | 1 |
| Au, WY; Chan, JC; Kwong, YL; Lam, CC; Leung, AY; Pang, A; Tse, E | 1 |
| Byrd, JC; Lee, RJ; Muthusamy, N; Wu, J; Zhao, X | 1 |
| Bettembourg, O; Cochard, C; Cochener, B; Roussel, B | 1 |
| Arai, Y; Doki, N; Ishida, F; Kano, Y; Kawai, Y; Komatsu, N; Miyawaki, S; Morii, T; Ogura, M; Ohno, R; Takeshita, A; Usui, N | 1 |
| Abella, E; Altés, A; Asensi, A; Aymerich, M; Bertazzoni, P; Bosch, F; Briones, J; Escoda, L; Ferrer, A; Font, L; Gardella, S; Giné, E; González, M; González-Barca, E; Montserrat, E; Muntañola, A; Pérez-Ceballos, E; Rozman, M; Sayas, MJ; Villamor, N | 1 |
| Baccarani, M; Derenzini, E; Fanti, S; Fina, M; Musuraca, G; Perrotti, A; Stefoni, V; Tani, M; Vitolo, U; Zinzani, PL | 1 |
| Anagnostopoulos, A; Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Papageorgiou, S; Psyrri, A; Tsatalas, C; Xiros, N | 1 |
| Altés, A; Asensio, A; Besalduch, J; Briones, J; Campo, E; Colomer, D; de Sevilla, AF; Domingo-Doménech, E; Escoda, L; Estany, C; Galán, P; Gardella, S; López-Guillermo, A; Montoto, S; Montserrat, E; Moreno, C; Oriol, A; Pedro, C; Ribera, JM; Vivancos, P | 1 |
| Chen, L; Lü, SQ; Ni, X; Song, XM; Wang, JM; Xu, XQ; Yang, JM; Zhang, WP | 1 |
| Baccarani, M; Cabras, MG; De Luca, S; De Renzo, A; Derenzini, E; Fabbri, A; Fanti, S; Fattori, P; Fina, M; Gobbi, M; Guardigni, L; Marchi, E; Musuraca, G; Pellegrini, C; Perotti, A; Piccaluga, PP; Pileri, S; Pulsoni, A; Rigacci, L; Ronconi, S; Stefoni, V; Tani, M; Voso, MT; Zaccaria, A; Zinzani, PL | 1 |
| Nabhan, C | 1 |
| Berthou, C; Dalbies, F; De Braekeleer, M; Feuerbach, J; Ianotto, JC; Le Bris, MJ; Marion, V; Tempescul, A | 1 |
| Adams, DJ; Decastro, CM; Gockerman, JP; Moore, JO; Peterson, BL; Petros, WP; Rao, AV; Rizzieri, DA; Sand, GJ; Spasojevic, I; Younis, IR | 1 |
| Chim, CS; Kwong, YL; Loong, F; Ng, WK | 1 |
| Angrilli, F; Baldini, L; Bari, A; Ilariucci, F; Lazzaro, A; Luminari, S; Marcheselli, L; Pozzi, S; Sacchi, S; Stelitano, C | 1 |
| Ben-Bassat, I; Bonstein, L; Gafter-Gvili, A; Raanani, P; Ram, R; Shpilberg, O | 1 |
| Kay, NE; Lamanna, N | 1 |
| Faderl, S; Ferrajoli, A; Keating, MJ; Lerner, S; O'Brien, S; Wierda, W | 1 |
| Janikova, A; Koristek, Z; Kral, Z; Mayer, J; Navratil, M; Pavlik, T; Sticha, M; Vasova, I; Vinklarkova, J | 1 |
| Hirayama, Y; Ishitani, K; Iyama, S; Kato, J; Kobune, M; Kohda, K; Koike, K; Kuroda, H; Neda, H; Sato, T; Takimoto, R; Terui, T | 1 |
| Aleksandrowicz, P; Dolińska-Krajewska, B; Draga, A; Dubielecka, PM; Grzybek, M; Jaźwiec, B; Kolondra, A; Kołodziejczyk, M; Kuliczkowski, K; Serwotka, A; Sikorski, AF; Warchoł, J | 1 |
| Golubeva, ME; Isaeva, NV; Kudriavtseva, AV; Malykh, OV; Tkachenko, SB; Zagoskina, TP | 1 |
| Brice, P; Copin, MC; Fermé, C; Feugier, P; Lamy, T; Morschhauser, F; Mounier, N; Sebban, C; Solal-Celigny, P; Tilly, H | 1 |
| De Brasi, C; Narbaitz, M; Noriega, MF; Rodríguez, A; Slavutsky, I | 1 |
| Ancliff, P; Darbyshire, P; Goulden, N; Green, N; Hancock, J; Leighton, C; Love, S; Masurekar, A; Moorman, AV; Morgan, M; Parker, C; Révész, T; Saha, V; Sutton, R; Waters, R | 1 |
| Booth, GA; Brown, J; Cocks, K; Cohen, DR; Dearden, C; Ezekwisili, R; Fegan, C; Hillmen, P; Kennedy, DB; Mercieca, J; Milligan, DW; Pettitt, A; Pocock, C; Radford, J; Rawstron, AC; Sayala, HA; Smith, AF; Varghese, AM | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Foon, KA; Hou, JZ; Luong, TM; Mehta, DR; Raptis, A; Redner, RL; Schlesselman, JJ | 1 |
| Cervigón, I; Palomo, A; Solano, F; Torres-Iglesias, LM; Zapata, AM | 1 |
| Argnani, L; Baccarani, M; Broccoli, A; Cavalieri, E; De Renzo, A; Derenzini, E; Fanti, S; Fina, M; Gandolfi, L; Montini, GC; Pellegrini, C; Pileri, S; Pulsoni, A; Quirini, F; Rossi, M; Scopinaro, F; Stefoni, V; Tani, M; Torelli, F; Zinzani, PL | 1 |
| Andresen, S; Bolwell, B; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sweetenham, J; Waterman, J | 1 |
| Bayer, R; Fung, HC; Gregory, SA; Karmali, R; Kassar, M; O'Brien, T; Shammo, JM; Venugopal, P | 1 |
| Argnani, L; Cabras, MG; Casadei, B; De Renzo, A; Derenzini, E; Fabbri, A; Gandolfi, L; Gobbi, M; Pellegrini, C; Perotti, A; Pulsoni, A; Rigacci, L; Voso, MT; Zaccaria, A; Zinzani, PL | 1 |
| Chen, DB; Shen, DH | 1 |
| Burgstaller, S; Drach, J; Einberger, C; Fridrik, M; Gaiger, A; Greil, R; Heintel, D; Hopfinger, G; Jäger, U; Mannhalter, C; Oberaigner, W; Porpaczy, E; Putman, M; Raderer, M; Skrabs, C; Zeitlinger, M | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C | 1 |
| Argnani, L; Baccarani, M; Broccoli, A; Casadei, B; Celli, M; Derenzini, E; Fanti, S; Gandolfi, L; Pellegrini, C; Pileri, S; Poletti, V; Quirini, F; Stefoni, V; Zinzani, PL | 1 |
| Busch, R; Cramer, P; Döhner, H; Eichhorst, B; Fingerle-Rowson, G; Fink, AM; Hallek, M; Herling, M; Hopfinger, G; Kandler, G; Pflug, N; Reinart, N; Stilgenbauer, S; Weit, N; Westermann, A; Winkler, D | 1 |
| Angrilli, F; Arcaini, L; Brugiatelli, M; Carella, AM; Dell'olio, M; Di Raimondo, F; Dondi, A; Federico, M; Franco, V; Gaidano, G; Galimberti, S; Luminari, S; Marcheselli, L; Merli, F; Pulsoni, A; Rigacci, L; Sacchi, S; Stelitano, C; Tucci, A; Vitolo, U | 1 |
| Dubielecka, PM; Grzybek, M; Korycka, J; Meissner, J; Michalczyk, I; Seweryn, E; Sikorski, AF; Toporkiewicz, M | 1 |
| Argnani, L; Broccoli, A; Casadei, B; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Alvarez De Celis, I; Baldini, L; Bari, A; Boccomini, C; Botto, B; Castellino, C; Chiappella, A; Chiarenza, A; Ciccone, G; De Angelis, F; De Renzo, A; Evangelista, A; Gamba, E; Ladetto, M; Lobetti-Bodoni, C; Parvis, G; Pinto, A; Rossi, G; Tucci, A; Vitolo, U; Zaja, F | 1 |
| Abella, E; Abrisqueta, P; Bobillo, S; Bosch, F; Calvo, X; Carbonell, F; Constants, M; Delgado, J; Escoda, L; Ferrà, C; Ferrer, S; García-Marco, JA; González, M; González, Y; González-Barca, E; Jarque, I; Montoro, JB; Montserrat, E; Monzó, E; Muntañola, A; Terol, MJ; Villamor, N | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L | 1 |
| Argnani, L; Broccoli, A; Casadei, B; Gandolfi, L; Maglie, R; Pellegrini, C; Pileri, S; Stefoni, V; Zinzani, PL | 1 |
| Hiroshima, Y; Ichikawa, N; Kirihara, T; Kobayashi, H; Kurihara, T; Mori, Y; Sato, K; Shibazaki, M; Sumi, M; Takeda, W; Ueki, T; Ueno, M | 1 |
| Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
| Alvarez, I; Anastasia, A; Arcari, A; Bari, A; Botto, B; Carella, AM; Chiarenza, A; Dondi, A; Federico, M; Marcheselli, L; Puccini, B; Salvi, F | 1 |
| Aulitzky, W; Bornhäuser, M; Ehninger, G; Fiedler, F; Hänel, A; Hänel, M; Herbst, R; Kroschinsky, F; Lange, T; Maschmeyer, G; Morgner, A; Neugebauer, S; Niederwieser, D; Peter, N; Pönisch, W; Schäfer-Eckart, K; Schetelig, J; Schulze, A; Thiel, A; Wilhelm, M | 1 |
| Bucur, S; Cohen, JB; Colbert, A; Flowers, CR; Heffner, LT; Hutchison-Rzepka, A; King, N; Langston, AA; Lechowicz, MJ; Lonial, S; Sinha, R; Waller, EK; Winton, EF | 1 |
| Kim, BS; Kim, HJ; Kim, JA; Kim, SJ; Kim, WS; Kong, JH; Park, SK; Park, Y; Shin, DY; Won, JH; Yoon, DH | 1 |
| Annechini, G; Argnani, L; Broccoli, A; Casadei, B; De Renzo, A; Gandolfi, L; Morigi, A; Pellegrini, C; Pulsoni, A; Quirini, F; Stefoni, V; Tonialini, L; Zinzani, PL | 1 |
| Altés, A; Asensio, A; Besalduch, J; Briones, J; Campo, E; Colomer, D; Domingo-Domenech, E; Escoda, L; Estany, C; Fernández de Sevilla, A; Gardella, S; González-Barca, E; López-Guillermo, A; Magnano, L; Montoto, S; Moreno, C; Muntañola, A; Oriol, A; Pedro, C; Ribera, JM; Salar, A; Sancho, JM; Vivancos, P | 1 |
| Bloor, A; Blundell, J; Fegan, C; Gribben, JG; Hamblin, M; Hillmen, P; Hockaday, A; Howard, DR; McParland, L; Munir, T; Pettitt, A; Phillips, D; Pocock, C; Rawstron, AC; Varghese, A | 1 |
| Ayala, A; Cabanillas, F; Fanale, MA; Fayad, L; Feng, L; Fowler, NH; Goy, AH; Hagemeister, FB; McLaughlin, P; Nastoupil, LJ; Neal, E; Neelapu, SS; Oki, Y; Rodriguez, MA; Romaguera, JE; Samaniego, F; Wang, M; Westin, JR | 1 |
| Angelucci, E; Angrilli, F; Arcaini, L; Bertoldero, G; Cascavilla, N; Chiarenza, A; Dondi, A; Federico, M; Ferrari, A; Ferreri, AJM; Gaidano, G; Kovalchuk, S; Luminari, S; Manni, M; Marcheselli, L; Merli, F; Pulsoni, A; Rusconi, C; Salvi, F; Stelitano, C; Tarantino, V; Tucci, A; Vallisa, D; Vitolo, U | 1 |
| Bahlo, J; Cramer, P; Dürig, J; Eichhorst, B; Fink, AM; Hallek, M; Herling, M; Hopfinger, G; Kreuzer, KA; Mayer, P; Oberbeck, S; Pflug, N; Robrecht, S; Schrader, A; Seiler, T; Stilgenbauer, S; Westermann, A; Zenz, T | 1 |
| Arai, Y; Hatsumi, N; Honda, S; Ishida, F; Kano, Y; Komatsu, N; Machida, S; Miyawaki, S; Morii, T; Naoe, T; Nishii, K; Ogura, M; Ohnishi, K; Takeshita, A; Usui, N; Yamauchi, T | 1 |
| Alonso Caballero, C; Barrenetxea Lekue, C; D'Amore, F; Grasso Cicala, S; Herráez Rodríguez, S; Jørgensen, JM; Leal Martínez, I; Leppä, S; Stauffer Larsen, T; Toldbod, H | 1 |
| Bishton, MJ; Clifton-Hadley, L; Haynes, A; Lush, R; McMillan, A; Patmore, R; Rule, S; Turner, D; Wilson, W | 1 |
13 review(s) available for fludarabine and mitoxantrone
| Article | Year |
|---|---|
Intracellular pharmacodynamics in leukemia therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; Humans; Leukemia; Mitoxantrone; Vidarabine | 1996 |
Clinical challenges in chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitoxantrone; Splenectomy; Vidarabine | 1998 |
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Cystitis; Cytarabine; Cytomegalovirus Infections; DNA, Neoplasm; Female; Foscarnet; Ganciclovir; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Prednisolone; Prostaglandins; Remission Induction; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2001 |
[Experience with fludarabine treatment and review of the literature].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dexamethasone; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Remission Induction; Treatment Outcome; Vidarabine | 2002 |
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Chlorambucil; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Forecasting; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2002 |
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Mitoxantrone; Rituximab; Vidarabine | 2003 |
Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bowen's Disease; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Fatal Outcome; Female; Hodgkin Disease; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Lomustine; Male; Middle Aged; Mitoxantrone; Neoplasms, Multiple Primary; Neoplastic Stem Cells; Prednisone; Prognosis; Reed-Sternberg Cells; Remission Induction; Skin Neoplasms; Splenectomy; Tumor Virus Infections; Vidarabine; Vinblastine; Vincristine | 2003 |
The role of mitoxantrone in the treatment of indolent lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Neoplasm Staging; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Survival Analysis; Vidarabine | 2005 |
[Current and new therapeutic strategies in acute myeloid leukemia].
Topics: Acute Disease; Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Disease-Free Survival; Etoposide; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Indoles; Leukemia, Myeloid; Mice; Middle Aged; Mitoxantrone; Piperazines; Prognosis; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Vidarabine | 2005 |
Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Complement Activation; Complement System Proteins; Cyclophosphamide; Cytokines; Drug Eruptions; Female; Fever; Humans; Leukopenia; Lymphoma, Mantle-Cell; Mitoxantrone; Risk Factors; Rituximab; Splenomegaly; Thrombocytopenia; Vidarabine | 2009 |
Pentostatin treatment combinations in chronic lymphocytic leukemia.
Topics: Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Administration Schedule; Forecasting; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Pentostatin; Rituximab; Salvage Therapy; Treatment Outcome; Vidarabine | 2009 |
[Specific palatal infiltration in B-cell chronic lymphocytic leukemia].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Castleman Disease; Cyclophosphamide; Diagnosis, Differential; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Middle Aged; Mitoxantrone; Palate, Soft; Red-Cell Aplasia, Pure; Rituximab; Vidarabine | 2011 |
Pixantrone beyond monotherapy: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Isoquinolines; Lymphoma, B-Cell; Mitoxantrone; Prednisone; Rituximab; Salvage Therapy; Vidarabine; Vincristine | 2019 |
66 trial(s) available for fludarabine and mitoxantrone
| Article | Year |
|---|---|
FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Recurrence; Vidarabine | 1995 |
Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Recurrence; Treatment Outcome; Vidarabine | 1997 |
Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Vidarabine | 1998 |
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Salvage Therapy; Treatment Outcome; Vidarabine | 1999 |
Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Survival Analysis; Vidarabine | 2000 |
A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; DNA, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Polymerase Chain Reaction; Recurrence; Treatment Outcome; Vidarabine | 2000 |
Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Mitoxantrone; Neoplasm Staging; Neutropenia; Rituximab; Vidarabine | 2000 |
Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Treatment Outcome; Vidarabine | 2001 |
Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure; Vidarabine | 2001 |
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance; Humans; Leukemia; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Therapeutic Equivalency; Treatment Outcome; Vidarabine | 2001 |
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Mitoxantrone; Remission Induction; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2001 |
Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Pilot Projects; Salvage Therapy; Survival Rate; Vidarabine | 2001 |
Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Mobilization; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Risk Factors; Survival Analysis; Treatment Outcome; Vidarabine | 2001 |
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
Topics: Actins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Dexamethasone; DNA; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mitoxantrone; Neoplasm, Residual; Polymerase Chain Reaction; Rituximab; Translocation, Genetic; Vidarabine | 2002 |
Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Remission Induction; Survival Analysis; Survival Rate; Vidarabine | 2002 |
Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisolone; Probability; Prognosis; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Tumor Burden; Vidarabine; Vincristine | 2002 |
Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisolone; Remission Induction; Vidarabine; Vincristine | 2002 |
Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Survival Analysis; Time Factors; Vidarabine | 2002 |
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Rate; Vidarabine; Vincristine | 2002 |
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Immunosuppressive Agents; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Time Factors; Vidarabine | 2002 |
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Recurrence; Survival Rate; Treatment Outcome; Tumor Cells, Cultured; Vidarabine | 2002 |
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Mitoxantrone; Rituximab; Vidarabine | 2003 |
Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Survival Analysis; Treatment Outcome; United States; Vidarabine | 2003 |
Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prognosis; Survival Rate; Vidarabine | 2004 |
A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.
Topics: Adolescent; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Survival Analysis; Time Factors; Vidarabine | 2004 |
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Vidarabine | 2004 |
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence; Rituximab; Survival Analysis; Vidarabine | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neutropenia; Opportunistic Infections; Remission Induction; Salvage Therapy; Survival Analysis; Vidarabine | 2004 |
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Risk Factors; Vidarabine; Vindesine | 2005 |
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 7; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; DNA Damage; Female; Follow-Up Studies; Humans; Immunotherapy; Interferon-alpha; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Mitoxantrone; Monosomy; Myelodysplastic Syndromes; Remission Induction; Rituximab; Time Factors; Vidarabine | 2005 |
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Germany; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Vidarabine | 2006 |
Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).
Topics: Adult; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Granulocyte Colony-Stimulating Factor; Humans; Japan; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence; Vidarabine | 2007 |
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2008 |
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Radioimmunotherapy; Survival Analysis; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2008 |
Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Remission Induction; Treatment Outcome; Vidarabine | 2008 |
High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Recurrence; Survival Rate; Vidarabine | 2008 |
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Italy; Kaplan-Meier Estimate; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Probability; Radioimmunotherapy; Risk Assessment; Survival Analysis; Vidarabine; Yttrium Radioisotopes | 2008 |
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Half-Life; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Salvage Therapy; Tissue Distribution; Vidarabine | 2008 |
Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Genes, bcl-2; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Prednisone; Remission Induction; Rituximab; Survival Analysis; Vidarabine; Vincristine | 2009 |
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cell Separation; Cyclophosphamide; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Pilot Projects; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2010 |
[Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphocytic leukemia].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunologic Factors; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Mitoxantrone; Myeloablative Agonists; Remission Induction; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2010 |
Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adult
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Rituximab; Tumor Burden; Vidarabine | 2010 |
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukocyte Count; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Assessment; Treatment Outcome; United Kingdom; Vidarabine; Vincristine | 2010 |
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2011 |
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Induction Chemotherapy; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Prospective Studies; Radioimmunotherapy; Rituximab; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2012 |
Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation.
Topics: Adult; Antineoplastic Agents; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Mitoxantrone; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors; Time Factors; Transplantation, Autologous; Vidarabine | 2012 |
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Radiopharmaceuticals; Rituximab; Survival Analysis; Vidarabine; Yttrium Radioisotopes | 2011 |
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lymphoma, Follicular; Mitoxantrone; Radioimmunotherapy; Vidarabine | 2012 |
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Pilot Projects; Prognosis; Prospective Studies; Remission Induction; Rituximab; Sex Factors; Survival Rate; Tissue Distribution; Vidarabine | 2012 |
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2012 |
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Prolymphocytic, T-Cell; Male; Middle Aged; Mitoxantrone; Proto-Oncogene Proteins; Remission Induction; Treatment Outcome; Vidarabine | 2013 |
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; Vincristine | 2013 |
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Lin
Topics: Age Factors; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Dexamethasone; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Rituximab; Vidarabine | 2013 |
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Neutropenia; Prospective Studies; Remission Induction; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2013 |
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2014 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphocyte Count; Lymphocytes; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Monocytes; Prednisone; Prospective Studies; Rituximab; Survival Rate; Vidarabine; Vincristine | 2015 |
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Routes; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Vidarabine; Young Adult | 2015 |
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Rituximab; Vidarabine | 2015 |
Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Hydroxamic Acids; Infusions, Intravenous; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Quality of Life; Recurrence; Vidarabine; Vorinostat | 2016 |
Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Survival Rate; Time Factors; Treatment Outcome; Vidarabine | 2017 |
Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Neutropenia; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Vidarabine | 2017 |
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Interferons; Lymphoma, Non-Hodgkin; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Remission Induction; Rituximab; Vidarabine; Young Adult | 2017 |
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.
Topics: Adult; Aged; Alemtuzumab; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Incidence; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Prolymphocytic, T-Cell; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Treatment Outcome; Vidarabine | 2019 |
Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Survival Rate; Vidarabine | 2019 |
The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Dexamethasone; Female; Follow-Up Studies; Genes, bcl-2; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Progression-Free Survival; Prospective Studies; Survival Rate; United Kingdom; Vidarabine; Young Adult | 2020 |
61 other study(ies) available for fludarabine and mitoxantrone
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Peptides; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2015 |
Effective treatment of relapsed acute myeloid leukaemia with drugs chosen by DiSC assay.
Topics: Acute Disease; Antineoplastic Agents; Cytotoxicity Tests, Immunologic; Drug Hypersensitivity; Etoposide; Female; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Recurrence; Vidarabine | 1992 |
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Diploidy; Etoposide; Female; Genetic Markers; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Philadelphia Chromosome; Remission Induction; Survival Rate; Vidarabine; Whole-Body Irradiation | 1995 |
Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Separation; Cytarabine; Daunorubicin; Diploidy; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Remission Induction; Vidarabine | 1995 |
The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells.
Topics: Antineoplastic Agents; Cell Cycle; Cytarabine; DNA Damage; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Humans; Immunoblotting; Leukemia, Myeloid, Acute; Mitoxantrone; Protein Binding; Tumor Cells, Cultured; Vidarabine | 1996 |
Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; DNA, Neoplasm; Endonucleases; Glucocorticoids; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Methylprednisolone; Mitoxantrone; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 1996 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 1999 |
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fever; Humans; Idarubicin; Immunocompromised Host; Infections; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; N-Formylmethionine Leucyl-Phenylalanine; Neutropenia; Neutrophils; Phagocytosis; Respiratory Burst; Retrospective Studies; Risk Factors; Thioguanine; Vidarabine | 1999 |
In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocyte Subsets; bcl-2-Associated X Protein; bcl-X Protein; CD3 Complex; Cyclophosphamide; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Vidarabine | 1999 |
Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (flan) treatment for acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hemorrhage; Humans; Infant, Newborn; Leukemia; Leukemia, Myeloid, Acute; Lung Diseases; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Respiratory Distress Syndrome, Newborn; Staphylococcal Infections; Vidarabine | 2000 |
Aggressive subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine, mitoxantrone and dexamethasone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Mitoxantrone; Panniculitis; Skin Neoplasms; Vidarabine | 2000 |
Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aged; Antineoplastic Agents; Apoptosis; Caspases; Cyclic Nucleotide Phosphodiesterases, Type 4; Down-Regulation; Drug Interactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Phosphodiesterase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Rolipram; Tumor Cells, Cultured; Vidarabine | 2001 |
Hematopoietic cell transplantation beyond first remission.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Cyclosporine; Cytarabine; Daunorubicin; Disease-Free Survival; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Nuclear Family; Prospective Studies; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Survival Rate; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Count; Cyclophosphamide; Dexamethasone; Enzyme Activation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Proteins; Middle Aged; Mitoxantrone; Protein Conformation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2002 |
Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confusion; Cytarabine; Etoposide; Fatal Outcome; Female; Gemtuzumab; Humans; Idarubicin; Immunotherapy; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Middle Aged; Mitoxantrone; Myocardial Infarction; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Therapeutics; Vidarabine | 2002 |
Segmental coecal cytomegalovirus colitis during fludarabine, cytarabine and mitoxantrone induction chemotherapy for myelodysplastic syndrome.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cecal Diseases; Colitis; Cytarabine; Cytomegalovirus Infections; Female; Humans; Middle Aged; Mitoxantrone; Vidarabine | 2002 |
Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Case Management; Chlorambucil; Cladribine; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Immunoglobulin M; Male; Middle Aged; Mitoxantrone; Plasmapheresis; Prednisone; Rituximab; Severity of Illness Index; Thalidomide; Vidarabine; Vinblastine; Vincristine; Vinorelbine; Waldenstrom Macroglobulinemia | 2003 |
Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine | 2003 |
Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Rituximab; Treatment Failure; Vidarabine | 2004 |
Reversible paraneoplastic neuropathy associated with T-cell large granular lymphocyte leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclosporine; Dexamethasone; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphoid; Male; Middle Aged; Mitoxantrone; Nerve Degeneration; Paraneoplastic Polyneuropathy; Paresthesia; Sural Nerve; T-Lymphocytes; Urinary Retention; Vidarabine | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Safety; Survival Rate; Treatment Outcome; Vidarabine | 2004 |
Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Coloring Agents; Cyclophosphamide; DNA Damage; Enzyme Inhibitors; Flow Cytometry; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Membrane Potentials; Mitochondria; Mitoxantrone; Proteins; Reactive Oxygen Species; Staurosporine; Time Factors; Translocation, Genetic; Tumor Suppressor Protein p53; Vidarabine | 2004 |
[Use of fludarabin in conjunction with other cytostatics in the treatment of non-Hodgkin lymphoma resistant to standard chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Treatment Outcome; Vidarabine | 2004 |
Changing the way we think about chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitoxantrone; Rituximab; Vidarabine | 2005 |
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell Cycle; Chlorambucil; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Activation; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Leukemia, Myeloid; Mitoxantrone; Paclitaxel; U937 Cells; Vidarabine | 2005 |
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; CD4-CD8 Ratio; Dexamethasone; Female; Humans; Immunosuppression Therapy; Infections; Interferons; Lymphoma; Male; Middle Aged; Mitoxantrone; Neutropenia; Vidarabine | 2005 |
[Treatment of refractory and relapsed acute lymphocytic leukemia in adults].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Teniposide; Treatment Outcome; Vidarabine | 2005 |
Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Agents; Cyclophosphamide; Cyclosporine; Dexamethasone; Drug Resistance, Neoplasm; Humans; Leukemia, T-Cell; Male; Mitoxantrone; Prednisolone; Red-Cell Aplasia, Pure; Remission Induction; Vidarabine | 2005 |
Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Male; Middle Aged; Mitoxantrone; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
[Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Dexamethasone; Doxorubicin; Female; Hemoglobins; Humans; Male; Middle Aged; Mitoxantrone; Multiple Myeloma; Myeloma Proteins; Neoplasm Recurrence, Local; Remission Induction; Vidarabine; Vincristine | 2005 |
Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Case-Control Studies; Cyclophosphamide; Fas Ligand Protein; fas Receptor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Glycoproteins; Middle Aged; Mitoxantrone; Solubility; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors; Vidarabine | 2005 |
PS exposure increases the susceptibility of cells to fusion with DOTAP liposomes.
Topics: Antineoplastic Agents; Apoptosis; Cell Membrane; Chlorides; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluorescent Dyes; HeLa Cells; Humans; Jurkat Cells; Liposomes; Manganese Compounds; Membrane Fusion; Mitoxantrone; Phosphatidylserines; Phospholipid Transfer Proteins; Quaternary Ammonium Compounds; Staurosporine; Vidarabine | 2006 |
Positron emission tomography--positive distal femur following fludarabine, dexamethasone and mitoxantrone chemotherapy.
Topics: Administration, Oral; Anti-Inflammatory Agents; Antineoplastic Agents; Dexamethasone; Femur; Humans; Injections, Intravenous; Male; Middle Aged; Mitoxantrone; Osteonecrosis; Positron-Emission Tomography; Vidarabine | 2006 |
Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Mitoxantrone; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine | 2006 |
[Mantle cell lymphoma mimicking chronic lymphocytic leukemia].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Diagnosis, Differential; Doxorubicin; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prednisolone; Rituximab; Vidarabine; Vincristine | 2005 |
The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Risk Factors; Rituximab; Vidarabine | 2006 |
[Remission in T-cell prolymphocytic leukemia during the FMC treatment course].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Leukemia, Prolymphocytic; Leukemia, T-Cell; Male; Middle Aged; Mitoxantrone; Remission Induction; Vidarabine | 2006 |
Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Leukemia, T-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Medical Oncology; Mitoxantrone; Treatment Outcome; Vidarabine | 2007 |
Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chemistry, Pharmaceutical; Drug Stability; Leukemia, Lymphocytic, Chronic, B-Cell; Liposomes; Mitoxantrone; Solubility; Vidarabine | 2008 |
[MALT (mucosa-associated lymphoid tissue) lymphoma of the lacrimal gland].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Eye Neoplasms; Humans; Lacrimal Apparatus; Lymphoma, B-Cell, Marginal Zone; Male; Mitoxantrone; Rituximab; Vidarabine | 2007 |
[A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Survival Rate; Thrombocytopenia; Vidarabine | 2007 |
Frontline therapy for chronic lymphocytic leukemia: the dilemma continues.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cost-Benefit Analysis; Cyclophosphamide; Drug Therapy; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Mitoxantrone; Research Design; Treatment Outcome; Vidarabine | 2008 |
A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Prolymphocytic, B-Cell; Male; Middle Aged; Mitoxantrone; Remission Induction; Rituximab; Vidarabine | 2009 |
Use of fludarabine-containing chemotherapeutic regimen results in durable complete remission of subcutaneous panniculitis-like T-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Mitoxantrone; Panniculitis; Skin Neoplasms; Vidarabine | 2008 |
Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Diseases; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cells; Humans; Interferon-alpha; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Prednisone; Procarbazine; Retrospective Studies; Rituximab; Vidarabine; Vincristine | 2009 |
[Successful induction of complete remission by gemtuzumab ozogamicin following chemotherapy in three patients with relapsed or refractory acute myeloid leukemia].
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Vidarabine | 2009 |
Aggregation of spectrin and PKCtheta is an early hallmark of fludarabine/mitoxantrone/dexamethasone-induced apoptosis in Jurkat T and HL60 cells.
Topics: Actins; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspase 3; Caspase Inhibitors; Cytoskeleton; Dexamethasone; Flow Cytometry; Fluorescent Antibody Technique; HL-60 Cells; Humans; Isoenzymes; Jurkat Cells; Mitoxantrone; Octoxynol; Protein Kinase C; Protein Kinase C-theta; Protein Multimerization; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrin; Vidarabine; Vimentin | 2010 |
Biclonal follicular lymphoma: histological, clinical and molecular characteristics.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chromosome Breakpoints; Clone Cells; Dexamethasone; Female; Gene Rearrangement; Genes, bcl-2; Humans; Lymphoma, Follicular; Mitoxantrone; Molecular Sequence Data; Neoplasm Staging; Polymerase Chain Reaction; Vidarabine | 2010 |
Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2011 |
[Classic Hodgkin's lymphoma in post-treatment hairy cell leukemia: report of a case].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Doxorubicin; Hodgkin Disease; Humans; Leukemia, Hairy Cell; Male; Mitoxantrone; Neoplasms, Multiple Primary; Rituximab; Splenectomy; Vidarabine; Vinblastine | 2011 |
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Disease-Free Survival; Drug Evaluation; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Mitoxantrone; Radionuclide Imaging; Retrospective Studies; Treatment Outcome; Vidarabine | 2013 |
Release of an ~55kDa fragment containing the actin-binding domain of β-spectrin by caspase-8 during FND-induced apoptosis depends on the presence of protein 4.1.
Topics: Actins; Amino Acid Sequence; Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Brain; Caspase 8; Caspase Inhibitors; Cytoskeletal Proteins; Dexamethasone; Drug Interactions; Erythrocyte Membrane; Humans; Jurkat Cells; Membrane Proteins; Mitoxantrone; Molecular Sequence Data; Protein Structure, Tertiary; Proteolysis; Spectrin; Swine; Vidarabine | 2013 |
Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prognosis; Recurrence; Retrospective Studies; Rituximab; Survival Analysis; Vidarabine | 2013 |
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Therapy; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2015 |
[Therapy-related chronic myelogenous leukemia following RFM therapy in a patient with follicular lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Rituximab; Vidarabine | 2014 |
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Positron-Emission Tomography; Remission Induction; Rituximab; Tomography, X-Ray Computed; Treatment Outcome; Vidarabine | 2016 |
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Follow-Up Studies; Humans; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Rituximab; Vidarabine; Vincristine | 2018 |